TY - JOUR
T1 - Sézary syndrome
T2 - Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
AU - Olsen, Elise A.
AU - Rook, Alain H.
AU - Zic, John
AU - Kim, Youn
AU - Porcu, Pierluigi
AU - Querfeld, Christiane
AU - Wood, Gary
AU - Demierre, Marie France
AU - Pittelkow, Mark
AU - Wilson, Lynn D.
AU - Pinter-Brown, Lauren
AU - Advani, Ranjana
AU - Parker, Sareeta
AU - Kim, Ellen J.
AU - Junkins-Hopkins, Jacqueline M.
AU - Foss, Francine
AU - Cacchio, Patrick
AU - Duvic, Madeleine
N1 - Funding Information:
Disclosure: Abbreviations are as follows: I (investigator), C (consultant), AB (advisory board), H (honoraria), S (speaker), RG (research grant, unrestricted, fellowship, etc).
PY - 2011/2
Y1 - 2011/2
N2 - Sézary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review of the published literature on therapeutic options for SS. An overview of the immunopathogenesis and standardized review of potential current treatment options for SS including metabolism, mechanism of action, overall efficacy in mycosis fungoides and SS, and common or concerning adverse effects is first discussed. The specific efficacy of each treatment for SS, both as monotherapy and combination therapy, is then reported using standardized criteria for both SS and response to therapy with the type of study defined by a modification of the US Preventive Services guidelines for evidence-based medicine. Finally, guidelines for the treatment of SS and suggestions for adjuvant treatment are noted.
AB - Sézary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review of the published literature on therapeutic options for SS. An overview of the immunopathogenesis and standardized review of potential current treatment options for SS including metabolism, mechanism of action, overall efficacy in mycosis fungoides and SS, and common or concerning adverse effects is first discussed. The specific efficacy of each treatment for SS, both as monotherapy and combination therapy, is then reported using standardized criteria for both SS and response to therapy with the type of study defined by a modification of the US Preventive Services guidelines for evidence-based medicine. Finally, guidelines for the treatment of SS and suggestions for adjuvant treatment are noted.
KW - Sézary syndrome
UR - http://www.scopus.com/inward/record.url?scp=78751571254&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751571254&partnerID=8YFLogxK
U2 - 10.1016/j.jaad.2010.08.037
DO - 10.1016/j.jaad.2010.08.037
M3 - Review article
C2 - 21145619
AN - SCOPUS:78751571254
SN - 0190-9622
VL - 64
SP - 352
EP - 404
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -